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This paper explores the views and expectations of patients concerning recontacting in clinical 
practice. It is based on 41 semi-structured interviews conducted in the UK. The sample 
comprised patients or parents of patients: without a diagnosis; recently offered a test for a 
condition or carrier risk; with a rare condition; with a Variant of Unknown Significance 
(VUS) – some of whom had been recontacted. Participants were recruited both via the 
National Health Service (NHS) and through online, condition-specific support groups. 
Most respondents viewed recontacting as desirable, however there were different opinions 
and expectations about what type of new information should trigger recontacting. An 
awareness of the potential psychological impact of receiving new information led some to 
suggest that recontacting should be planned, and tailored to the nature of the new information 
and the specific situation of patients and families..  
The lack of clarity about lines of responsibility for recontacting and perceptions of resource 
constraints in the NHS tended to mitigate respondents’ favorable positions towards 
recontacting and their preferences. Some respondents argued that recontacting could have a 
preventative value and reduce the cost of healthcare. Others challenged the idea that 
resources should be used to implement formalized recontacting systems – via arguments that 
there are ‘more pressing’ public health priorities, and for the need for healthcare services to 
offer care to new patients.  
 
Keywords: recontacting; next generation sequencing; ethics; clinical genetics; patients 
INTRODUCTION  
The rapid accumulation of new genetic and genomic knowledge is resulting in better 
diagnosis and treatment of some health conditions. Patients seen by a genetics service may 
not have received a diagnosis in the past (due to insufficient knowledge of certain disorders) 
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or may have had a diagnosis, but advances in medical science may bring new information as 
well as treatment or management options.  This deluge of new clinical information is 
intensified by the increasing use of whole exome or genome approaches in healthcare, where 
variants of previously unknown significance (VUSs) may be reclassified as pathogenic or 
non-pathogenic [1]. As more knowledge is accrued, the question of whether former patients 
should be recontacted, when updated information about their genetic variants is available, 
becomes more pressing.   
There is a growing interest internationally in addressing the problem of recontacting – given 
the familial, predictive nature of genetic information and the fact that the significance of such 
information may change [2-6]. However, as discussed elsewhere [7, 8], there is no consensus 
over whether and in what circumstances healthcare professionals (HCPs) should recontact 
patients, and there is also limited research on this topic.  
Ethical arguments have been made in favour of recontacting, mostly on the ground that new 
genetic/genomic information can have significant implications for the health of patients and 
families, and their reproductive decisions, lifestyle choices, employment, and psychosocial 
wellbeing [9, 10].  However, existing empirical evidence indicates that not all patients value 
recontacting and some would prefer not to be recontacted [11, 12]. Recontacting may also 
affect patients negatively, causing anxiety and concerns over health and economic activity, 
and may be experienced as an intrusion into privacy and a violation of their interest [13] or 
right not to know (RNTK) [14, 15]. 
A systematic review [11] about recontacting points to a clash between the ethical desirability 
and the practical difficulty, due mostly to lack of resources, of recontacting.  It also argues 
that, resources aside, there are many other aspects of recontacting that need investigation, e.g. 
clarifying the situations in which recontacting is seen as a good standard of care, as well as 
role boundaries and responsibilities. 
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Some have argued that the task of recontacting should be performed by the medical 
specialist(s) who provides continuity of care to patients, which is often their general 
practitioner (GP)[10]. However studies that explored  patients’ and genetic HCPs’ views on 
recontacting found that both groups identified genetic HCPs as having responsibility to 
perform this task [9, 16]. However, genetic HCPs tended to assign more responsibility to 
patients for maintaining contact with HCPs than patients [9].. Some commentators have 
suggested that support groups – through regular newsletters and by posting news on their 
websites – may play a role in recontacting [17-20].  
Our research has for the first time explored current practices and the views of HCPs and 
clinical scientists in the UK. We reported that recontacting was viewed as desirable under 
certain circumstances [7, 8]. However, in line with the systematic review [11],  there was a 
widespread concern about its feasibility due to insufficient resources and lack of clarity about 
role boundaries and responsibilities. Clarifying these issues was seen as a pre-requisite to the 
development of guidelines. The importance of bridging the ‘gap’ between the expectations of 
patients and those of HCPs was also highlighted [7]. The crurent paper paper aims to address 
this gap by presenting the results from interviews with patients which explored their views 
and expectations about recontacting.    
METHOD 
These interviews are part of a broad interdisciplinary study which investigates clinical, 
ethical, legal and social issues related to recontacting in clinical genetics practice in the NHS 
in the United Kingdom (study website: http://ex.ac.uk.//mgc). The aim of these interviews 
was to investigate qualitatively patients’ expectations about how genomic information is 
managed and their expectations regarding responsibilities and mechanisms for recontacting 
The study obtained approval from a NHS Research Ethics Committee; this allowed the 
recruitment of participants via regional genetics services, covering a combined population of 
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around 8 million. Data collection took place between 2015-16. Local collaborators at each 
site sent out study information and interested parties contacted the researchers directly. We 
did not ask them to record the number of patients they contacted, so we are unaware of our 
response rate. To broaden the sample we recruited participants by posting information about 
our study on online condition-specific support groups. Participants were 41 patients or 
parents thereof. Conditions were self-reported: 18 had a condition that was rare (e.g. 
myotubular myopathy) or undiagnosed; 11 had a suspected hereditary cancer or cardiac 
condition for which the genetic basis had not been found (i.e. BRCA1/2-negative breast 
cancer, or a VUS); and 12 had a diagnosis that was clearer (e.g., hereditary breast cancer or 
Fragile X). All were potentially ‘eligible’ for being recontacted—either for a test, a variant 
reclassification, or because a newly identified risk-reducing intervention was available.  Four 
had been recontacted by the genetic service, who offered the patient a test where one was 
previously unavailable; four were recruited through support groups – none of these had been 
recontacted  (for more details about the sample see Table 1).. Interviews were semi-structured 
and face-to-face, except for two which were conducted by telephone. Questions were open-
ended and investigated: experiences of genetic testing and/or having been recontacted by a 
HCP; potential expectations and preferences; and ideas about potential lines of responsibility. 
Interviews were recorded, transcribed verbatim and subjected to thematic analysis [21]. They 
were conducted and independently analysed by three members of the research team (co-
authors 1-3). Key themes were identified and discussed in regular team meetings, and with 
co-authors. Some of the quotations used in this paper have been slightly edited for 
readability. Parents of patients were interviewed together and are ascribed a double 
hyphenated number, e.g. P1-2. The interview guide is provided as Supplementary 







Pro Recontacting  
The majority of respondents valued recontacting.  New genetic/genomic information was 
generally linked to an improvement in the knowledge about a condition, or strategies of 
disease management or prevention – and was therefore seen to benefit both patients and 
family members. 
P2 Forewarned is forearmed isn’t it, because then, if there’s something preventative 
that you can do to, [it] doesn’t rule you out from getting it but [...] your chances are 
better  
Some comments suggested an interpretation of recontacting as in line with a ‘long-sighted’ 
healthcare system – in which some resources are used to leverage medical innovation to 
prevent or reduce the severity of diseases (as opposed to a ‘fire-fighting’ approach in which 
resources are mainly used to treat overt manifestation or severe symptoms)       
P5 Healthcare is not just there at the point of crisis, that's the point of where you are 
in dire need and you need a lifesaving operation or it should look after you or it 
should be there, be available to you throughout being ill, preventing you being ill, 
recovering, and helping you live a healthy life beyond any illness 
It is important to highlight there were different degrees of endorsement of recontacting. Many 
respondents’ comments revealed not only a preference, but also an expectation to be 
recontacted in light of new information, and/or the suggestion of the concept of a professional 
responsibility to recontact patients.  
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P40 If the information is there I think it should be given to somebody.  I don’t think 
there’s any point in holding back 
P7 I would definitely, a thousand percent want to know. […] I think you’ve got an 
obligation to pass this information on  
Some instead regarded recontacting as desirable, but not necessary; and others – like the 
respondent below – deployed a low degree of endorsement, appearing almost neutral about 
the utility of recontacting (see also ‘Resources’ section).  
 P6 I wouldn’t object but I, I mean, I wouldn’t regard it [recontacting] as essential 
Different thresholds of significance of new information  
Respondents’ views about what kind of new information was significant, or would 
correspond to a professional responsibility to recontact varied. Most expressed the 
preference, or expectation, to be recontacted in relation to new information that is clinically 
significant/actionable and, crucially that is tailored specifically to them or their family. This 
example below from a respondent with cardiomyopathy is revealing:  
P23 [I would expect to be recontacted] if there’s something significant that would be 
relevant to me and my particular condition. [...], but if it was just a case of, “Oh 
we’ve found a new gene that causes cardiomyopathy, we are just letting you know”, 
then no, I wouldn’t expect that 
However, some respondents – especially parents of children with genetic conditions – valued 
the possibility to receive any type of new information, irrespective of its clinical 
significance/actionability, or specificity. For this group new medical information as such was 
associated with a greater chance of understanding and exerting control over one’s or a family 
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member’s condition (e.g. a more nuanced understanding of the causes, or getting closer to a 
diagnosis). 
P13-14 We’d rather know everything which would help the boys, we feel that the 
more you know about something… it’s better to prepare or understand, isn’t it? 
P10-11 By greater understanding, it gives you a reason to know why it’s happening.
 … I’d rather that correct information comes to us as soon as they find it 
P28 I think ignorance is not always bliss, is it? If something happened and we didn't 
know, we could have done something to prevent it…I think it's important to know if 
there's something that can be done to help, definitely 
Some respondents placed emphasis on having regular contact with the healthcare service, 
expressing eagerness to be notified also about the lack of new information. This preference – 
which stretches recontacting to a form of regular follow-up –  gave voice to a perceived 
difficulty in managing the uncertainty (in terms of risk/diagnoses/prognoses) that genetic and 
genomic medicine can generate, and the related challenge of dealing with what was perceived 
as the slow pace of clinical practice and research.  
P12 We’ve learnt with genetics, “soon” can mean anything between one and two 
years 
 P22  Even if it’s: “We haven’t found anything”[…]I would just like to know, because 
it’s just like a waiting, isn’t it? You just think “ooh, I wonder if they have found 
anything” or “I wonder if anything has happened” or ‘how’s it all going?” 
P31 I’d like to be kept informed like annually maybe […] there is the element of 




The complexity of receiving new information  
Respondents deployed diverse and nuanced accounts of the potential psychological effects of 
receiving new information.  Some expressed their eagerness to receive updates even when 
new information is not linked to improvement of health outcomes   
P34 I think knowledge is power.  I would want to know.  Even if it was really bad, I’d 
want to know.  If they said “actually everyone who’s got this is going to be dead in 
ten years”, I’d want to know [...] and then I can live my life accordingly 
Others voiced concerns about the psychological impact that recontacting may have for both 
themselves, or other patients – in particular if the new information was perceived as not 
linked to an improvement of health outcomes 
P5 I suppose being very blunt about it, if the information you are given leads to bad 
news, would you want to know that, do you know what I mean? I mean probably me, 
probably yes, but I could imagine a lot of people wouldn't want that 
Concrete examples of the complex psychological impact of receiving new information – 
irrespective of its perceived positive or negative value – were provided by the few 
respondents who had experienced being recontacted. The quotation below illustrates how a 
positive attitude towards being recontacted, and a feeling of gratitude, do not counter the 
potential psychological complexity of the experience  
P20 It was only about three months ago. I wasn’t expecting a hospital letter. And it 
did throw me. […] I can’t explain why because to me it was brilliant, I was really 
glad that things had moved on, but it was still quite a shock that I thought, maybe I’d 
get an answer now [...] I had a long chat with [consultant who recontacted 
respondent] on the phone then before I went to see him. And I was honest with him, I 
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said, “You’ve completely floored me”. It was just completely out of the blue, really, 
but in a good way  
Another important point made was that recontacting should be planned, according to the 
nature of the new information and the specific patient. This point concurs with the above-
mentioned preference expressed by some respondents to receive bespoke information   
P34 If it was a significant development, that was going to be very impacting or life-
limiting, then I think that would need to be quite carefully managed in terms of how 
that information is given to people.  It wouldn’t necessarily have to be a face-to-face 
appointment, [it] would just have to be quite carefully managed, which I have every 
faith that it would be 
An interesting corollary was the suggestion to ‘coordinate’ recontacting with timely access to 
the clinical service, to offer patients the opportunity to discuss the new information and its 
implications with HCPs.  The quotation below vividly illustrates this point. 
P12 The worse you can have, is “Oh I’ve got information, but I can’t see you until 
two months” 
Right Not To Know  
The so called patient ‘right not to know’ (RNTK) was another contentious aspect related to 
the complexity of receiving new information.  Some respondents argued that patients who 
have expressed a desire not to be recontacted should be recontacted anyway – especially if 
the new information is clinically relevant. This group placed more emphasis on HCPs’ duty 
of care and/or the utility of receiving new information, than on patients’ RNTK 
P7 I think it’s a duty of care…whether they [patients] want to hear it or not sometimes 
you have to hear things you don’t want to know 
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Others, whilst acknowledging the potential tension between HCPs’ duty of care and patients’ 
RNTK, emphasised the importance of respecting patients’ preferences. Like the respondent 
below, some added that this view presupposes that the preference is made in a condition of 
full capacity 
P23 If the patient is mentally fit and has said they don’t want to hear anything further, 
then I think their wish should be respected because it’s up to them. Obviously, there 
will be exceptions to that in the case of people that aren’t capable of making decisions 
such as that, but if such as myself or my brother, if we said, “No, we don’t want to 
hear anything further”, then I would expect that to be respected. […] It’s a difficult 
one because obviously the responsibility is with the consultant, I suppose they would 
want to inform the patient, but if the patient has said they don’t want to know then 
they can’t force them to know 
Some expressed more nuanced compromises based on the suggestion that recontacting – and, 
in general, the HCP-patient relationship – should be seen as an open process in which both 
patients and HCPs have the possibility to get back in touch when appropriate. Again this 
suggestion stretches recontacting to a form of follow-up.   
P30 I think they should respect your decision, but maybe periodically ask if that is 
still the way you feel. 
P37 I think they ought to leave the door open.  They ought to be able to say to them, 
“Look I know you find this devastating today, but next week, when you’ve had time to 
think about it or calm down or talk to somebody else about it, you might want to come 
back to me” 
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Unclear responsibilities  
Respondents found it challenging to link their recontacting preferences and expectations to 
ideas about roles and responsibilities. There was a general agreement that there should be no 
time limit for this responsibility. This reinforces the idea of the benefit of receiving updates 
presented above 
P29  You can’t put a time limit on it, because we’re always going to be finding out 
something new about it, so no there shouldn’t, well why would there be a time limit, it 
seems a silly thing to put a stop on it. It’s like saying, oh, we’re going to stop the 
research now, it’s, what we know is all we want to know, we don’t want to know 
anymore. 
There were however mixed and divergent opinions about who should be responsible for 
recontacting.  A relatively common position was that genetic HCPs should be responsible, as 
they were identified as the specialty with the expertise to understand, and keep up to date 
with, developments in genomic medicine. 
P7 I think now genetics have stoked it all up, I think they have got a little bit of an 
obligation now to keep me in the loop 
Emphasising the logistical aspects of recontacting, some argued for the involvement of GPs, 
mostly on the grounds of being the speciality with the most up-to-date patient demographic 
and clinical information, and an efficient system that could be leveraged for recontacting 
purposes 
P17 Perhaps by then people have changed the address or ... and haven't contacted 
them [genetic HCPs] and let them know.  I think if it's done through their GPs, their 
GP will always have an up to date address.  If I let my GP know they'll always have 
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my up to date address so then they'll always be able to get back to me on any new 
findings…because it could take years to find anything out  
Others placed emphasis on the HCP-patient relationship, arguing that ideally the HCPs who 
are involved in the management of the patient, or are more ‘familiar’ with the patient, should 
be those responsible for recontacting them. The quotation below illustrates this point and, 
drawing on the general decline of continuity of care within Primary care in the NHS, it also 
challenges the idea that GPs should be involved in recontacting   
P8 I don’t think it could be the GP. Twenty years ago when you had a family GP it 
would be different but we don't anymore. I see a different GP every time I go. I think it 
should come from not necessarily the person you saw because that might not be 
possible, but if possible the person that has been involved in your care. I think it 
should come from somebody that you are aware of already  
Along a similar line of argument, there were respondents who explicitly resisted the idea that 
one speciality should be responsible, claiming instead that this responsibility should be 
distributed across the HCPs and specialties involved in the management of the patient.  
Some extended this responsibility to patients – suggesting that patients could contact HCPs 
(genetic or other specialties involved) to ask for updates  
P30 I think it’s everyone’s responsibility.  But I think there needs to be some kind of 
mechanism there to bring everyone back together, you know periodically, to go over 
that.  [...] The professionals have access to tools that we don’t, that give them 
information that we would never have access to, so that’s why it needs to be both  
As the quotation above shows, the argument of patients’ involvement was generally not 
framed as a complete transfer of responsibility for recontacting onto patients, but rather as a 
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joint venture between patients and HCPs, enabled by some form of infrastructure or 
governance [22]. This idea of joint venture was principally justified drawing on widespread 
discourses about each patient’s responsibility for managing their own health, and/or as being 
a sustainable way to enact recontacting within the resource-constrained NHS [22].  
There were contradictory views about a potential responsibility of support groups. Those in 
favour tended to use the following arguments: support groups may have more resources than 
the NHS to use for recontacting purposes, and they may be effective communicators of 
updates as they are more in tune with the psychosocial dimension of living with genetic 
conditions, as opposed to the biomedical approach of HCPs [23]  
P13 I think they probably would be better at doing it because they also get funded and 
a lot of people raise money for them, so maybe you know they would be better to do it 
on their behalf 
P38…the NHS is such a big organisation, it’s very clinical, where the patient support 
group is pertaining to what you’ve had or got or likely to get or it’s dealing with what 
you are sort of going through, so it’s a bit more personal.  So yeah, I would think they 
have got a role 
The main arguments of those who were against were the opposite, i.e. they revolved around 
the idea of the financial status and lack of resources of support groups, that medical updates 
should be communicated to patients by HCP, and that patients do not always want to join 
support groups.  
P2  I think there’s a place in society for them to support these people, but I think that 
information needs to come from somebody medically qualified … 
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P29 …They’re a charity at the end of the day and they could fold tomorrow.  And it’s 
difficult for them, [...]and as the research gets bigger and bigger, they’re not going to 
be updating every newsletter, every month, every 6 months, they might only do one 
every 18 months or 2 years, which might be too late, as research moves on. 
Finally, it is important to point out that the general lack of clarity about recontacting 
responsibility appeared to be intensified by discourses of resource issues.  
P35 I know everybody’s busy in the NHS, but where does it stop? Do you start a new 
role?   
Resources  
An awareness of a lack of resources and cuts in the NHS challenged or weakened 
respondents’ recontacting preferences, expectations, and ideas about responsibilities.  For 
example, many of those who favoured recontacting struggled to imagine its implementation, 
recognising that the sustainability of the NHS is already at stake with the current levels of 
services, staff, time and other resources.  
Broad challenges were also recognised; the most common revolved around the idea that 
resources should be invested to tackle more urgent public health priorities (e.g. diabetes, 
obesity). Another broad and related challenge mentioned was the priority to offer a service to 
new patients, before investing resources to recontact former patients:    
P1 It's just impossible isn't it, I don’t think they cope, I think they do a marvellous job 
but there's just not the resources there, are there, it's as much as they can do to cope 
with the new cases that keep coming along, never mind those that are in the past  
As the extract below illustrates, the awareness of resource constraints could influence the 
degree of endorsement of recontacting described in the section ‘Pro Recontacting’  
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P18 It [recontacting] would be helpful, yeah.  If they've got the time and resources to 
do that then it doesn't matter 
Finally, there were respondents who attempted to find a compromise between their 
preferences and their perception of the current status of the NHS, suggesting models of 
recontact that would be more ‘basic’ and require fewer resources. For example, the passage 
below illustrates a proposal of a model of sustainable implementation in which the bespoke 
elements of recontacting are sacrificed     
P5 I probably don't expect it because I think I've experienced how inundated 
healthcare professionals are in the day to day treatment of patients. [..]But I do think 
it would be helpful and beneficial if it could happen. But then it would probably have 
to happen on a general basis rather than on a very personal basis 
 
DISCUSSION 
Overall these findings indicate that patients tend to value the potential for recontact as an 
important means to bring the clinical and psychological benefits of biomedical research to 
families in a timely fashion. As in our study based on interviews with HCPs [7], there was a 
lack of clarity about lines of responsibility for recontacting and a tension between its 
desirability and its feasibility. The lack of clarity and the perception of resource constraints 
tended to weaken respondents’ favourable assessment of recontacting and to downgrade their 
expectations of it in practice. These assessments and expectations were also weakened in the 
light of ethical considerations relating to justice. Some respondents challenged the idea that 
resources should be used to implement recontacting, drawing on ethical arguments about the 
existence of more pressing public health priorities and the need for healthcare services to 
offer care to new patients. However, others claimed for recontacting a value in the prevention 
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of disease or diminution of risk and, thereby, a potential reduction of healthcare costs. These 
individuals were therefore more in favor of its implementation in practice within the NHS.     
There were different views concerning the type of information patients would expect to 
receive in any recontact, in line with research on the personal utility of genetic information 
[24, 25]. However, respondents’ accounts – e.g. the ideas that HCPs should plan recontacting, 
and the suggestion that the HCPs ‘known’ to the patients and/or involved in the management 
of their condition should be involved – pointed to a recognition that in certain circumstances 
receiving new information may trigger complex psychological reactions, irrespective of how 
bespoke or actionable the new information might be. This recognition validates the 
suggestion that a discussion between HCPs and patients about recontacting in the context of 
consent for testing may be beneficial [26]. Such discussion may help patients to reflect on the 
issue of the evolving nature of genomic information, adjust their expectations about the 
possibility of accessing new information (also in the light of what the healthcare service can 
offer) and express their preferences. It may also help the HCPs to gather some information 
that may enable them to offer a form of recontacting that would be in line with patients’ 
preferences, reducing the potentially negative psychological effects.   
Interestingly, the idea that GPs may be involved in recontacting was mostly justified on the 
ground of their patient records – rather than on the argument presented previously in the 
literature  that they provide continuity of care [10].   
It appears unlikely that support groups could play a central role in updating patients about 
personally-tailored  genomic information, given their potentially precarious financial status, 
and that not all patients seen by HCPs may end up joining these groups [27]. However, the 
question about whether they may play a role in relation to specific conditions remains open. 
Some respondents suggested that support groups may be in a suitable position to convey new 
information because more in tune with the psychosocial dimension of living with genetic 
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conditions. This gives emphasis to the idea of the potential complex psychological impact of 
receiving new information.   
There was an adequate understanding of what recontacting means, partly because the 
interviewers had the opportunity to explain and provide examples of recontacting scenarios 
during the interview. Nevertheless, despite the effort to frame the interviews as focusing on 
recontacting in clinical practice, some respondents tended to conflate the clinical and research 
dimensions.  Moreover, some stated preferences (e.g. to receive regular updates from HCPs) 
corresponded to a model of follow-up (i.e., never being discharged from the service) rather 
than recontacting (i.e., being contacted after being discharged). This raises the question of 
how recontacting should be defined. Otten et al.’s systematic review defines recontacting as 
the ethical and/or legal obligation to recontact former patients in light of new genetic findings 
[11]. We follow this definition, although we have previously highlighted that there are 
important distinctions between ‘duty’ and ‘responsibility’ [7].  A related challenge is to 
clarify what ‘former patients’ means in practice. Recontacting suggests a new contact with a 
patient, previously discharged from care, due to the emergence of new information. This 
definition implies a difference between recontacting and follow-up. However, as this research 
shows, this difference may not be relevant to some patients and some HCPs who do not 
formally discharge their patients (e.g. genetics/cardiology). The boundaries between 
recontacting and follow-up may also vary in other countries with different models or systems 
of healthcare. We suggest that it is important to agree an operational definition of 
recontacting that could be useful to HCPs, clinical scientists, and patients across different 
countries.  
This study has some limitations. A small proportion of respondents had been recontacted,  
and we think that it would be important to investigate potential differences between this 
group and  those for whom recontact is a hypothetical issue. Interviews were undertaken in 
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the UK which has a National Health Service and a long-established clinical genetics service. 
However rigorous investigations of views and expectations of patients from the UK could be 
effectively shared in the European context, at least with countries with clinical genetics 
services framed in a national health system.  
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